The National Institute for Health and Care Excellence

First new NHS treatment in over 20 years recommended for women with resistant ovarian cancer

We’ve recommended mirvetuximab soravtansine (also called Elahere and developed by AbbVie) for treating folate receptor-alpha-positive platinum-resistant epithelial ovarian, fallopian tube or primary ...
The National Institute for Health and Care Excellence

New guidance on 'artificial pancreas' technology for pregnant women with type 1 diabetes

Ahead of Diabetes Awareness Week, an independent NICE committee has recommended that a pregnancy-specific version of this technology should be offered when planning a pregnancy. Managing blood sugar ...
National Institute for Health and Care Excellence

Falls: assessment and prevention in older people and in people 50 and over at higher risk

This guideline covers assessing risk of falling and interventions to prevent falls in all people aged 65 and over, and people aged 50 to 64 who are at higher risk of falls. It aims to reduce the risk ...
National Institute for Health and Care Excellence

Durvalumab with chemotherapy for neoadjuvant and adjuvant treatment then alone for adjuvant treatment of resectable gastric or gastro-oesophageal junction adenocarcinoma

There is a commercial access agreement for durvalumab. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact ...
National Institute for Health and Care Excellence

Lisocabtagene maraleucel for treating relapsed or refractory large B-cell lymphoma after 2 or more lines of systemic treatment

There is a simple discount patient access scheme for lisocabtagene maraleucel. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact ...
The National Institute for Health and Care Excellence

Why flexibility is built into everything we do at NICE Advice

No two products are the same, so no two NICE Advice projects should be either. Andrew Walsh explains how NICE Advice adapts ...
National Institute for Health and Care Excellence

Published guidance, NICE advice and quality standards

Lisocabtagene maraleucel for treating relapsed or refractory large B-cell lymphoma after 2 or more lines of systemic treatment TA1159 3 June 2026 3 June 2026 Durvalumab with chemotherapy for ...
National Institute for Health and Care Excellence

Medicines management

Critical assessment of evidence to help you make decisions. Advice, rather than formal NICE guidance.
National Institute for Health and Care Excellence

Tisotumab vedotin for treating recurrent or metastatic cervical cancer that has progressed on or after systemic treatment

There is a simple discount patient access scheme for tisotumab vedotin. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact Genmab at ...
National Institute for Health and Care Excellence

Rheumatoid arthritis in adults: management

Guidance Standards and indicators Clinical Knowledge Summaries (CKS) British National Formulary (BNF) BNF for Children (BNFC) Life sciences Library and knowledge services What NICE does Implementing ...
National Institute for Health and Care Excellence

7 Treating status epilepticus, repeated or cluster seizures, and prolonged seizures

Provide resuscitation and immediate emergency treatment for children, young people and adults who have convulsive status epilepticus (seizures lasting 5 minutes or more). If the person with convulsive ...